Profile data is unavailable for this security.
About the company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
- Revenue in CHF (TTM)47.99m
- Net income in CHF14.79m
- Incorporated2002
- Employees22.00
- LocationNewron Pharmaceuticals SpAvia Antonio Meucci 3BRESSO 20091ItalyITA
- Phone+39 26103461
- Fax+39 261034654
- Websitehttps://www.newron.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RELIEF THERAPEUTICS Holding SA | 8.42m | -17.12m | 29.91m | 31.00 | -- | 0.7268 | -- | 3.55 | -1.37 | -1.37 | 0.6712 | 2.92 | 0.1299 | 3.22 | 4.73 | 271,516.10 | -26.42 | -33.04 | -29.08 | -35.76 | 69.41 | -- | -203.39 | -874.66 | 3.74 | -- | 0.0552 | -- | 39.52 | -- | 82.56 | -- | -- | -- |
| Xlife Sciences AG | 834.88k | 34.28m | 113.97m | 17.00 | 4.25 | 0.3734 | 2.55 | 136.52 | 4.67 | 4.67 | 0.1137 | 53.16 | 0.0016 | -- | 0.0949 | 49,110.59 | 5.46 | 6.01 | 6.76 | 7.37 | 65.82 | 37.44 | 3,438.40 | 2,987.92 | 1.53 | -- | 0.1301 | -- | -15.54 | 10.15 | 130.37 | 100.79 | -13.48 | -- |
| Molecular Partners AG | 4.97m | -54.04m | 120.52m | 159.00 | -- | 0.7769 | -- | 24.25 | -1.59 | -1.59 | 0.1457 | 3.84 | 0.0279 | -- | 2.33 | 31,257.86 | -30.29 | -13.09 | -32.59 | -15.66 | -- | 99.25 | -1,087.38 | -56.51 | -- | -- | 0.017 | -- | -29.38 | -24.59 | 12.81 | -- | -17.26 | -- |
| Newron Pharmaceuticals SpA | 47.99m | 14.79m | 134.41m | 22.00 | 8.45 | 98.72 | 8.98 | 2.80 | 0.797 | 0.797 | 2.59 | 0.0682 | 1.14 | -- | 2.33 | 2,181,211.00 | 35.30 | -23.70 | 84.85 | -32.05 | 98.26 | 97.14 | 30.83 | -69.33 | -- | 6.07 | 0.9719 | -- | 467.41 | 48.83 | 197.65 | -- | -23.92 | -- |
| BioVersys AG | -100.00bn | -100.00bn | 201.89m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.28 | -- | -- | -- |
| Idorsia Ltd | 161.33m | -230.50m | 492.36m | 938.00 | -- | -- | -- | 3.05 | -1.37 | -1.37 | 0.7856 | -5.57 | 0.2609 | 0.5722 | 5,866.66 | -- | -37.27 | -48.63 | -93.44 | -61.12 | 78.41 | -- | -142.87 | -526.39 | 0.3785 | -41.16 | 42.60 | -- | -26.17 | 36.41 | 11.47 | -- | -1.08 | -- |
| Basilea Pharmaceutica AG Allschwil | 208.54m | 77.59m | 625.74m | 164.00 | 8.40 | 7.02 | 7.88 | 3.00 | 5.59 | 5.59 | 15.05 | 6.70 | 0.9676 | 1.33 | 11.34 | 1,271,604.00 | 36.00 | 7.08 | 45.93 | 11.18 | 81.45 | 82.50 | 37.21 | 9.96 | 4.16 | 20.89 | 0.5422 | -- | 32.30 | 9.19 | 642.45 | -- | 34.71 | -- |
Data as of Jul 01 2025. Currency figures normalised to Newron Pharmaceuticals SpA's reporting currency: Swiss Franc CHF
6.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 20 Sep 2024 | 599.76k | 3.01% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Apr 2025 | 369.16k | 1.85% |
| Baader Bank AG (Investment Management)as of 31 Mar 2025 | 155.00k | 0.78% |
| Heights Capital Management, Inc.as of 25 Jul 2024 | 75.01k | 0.38% |
| Pictet Asset Management SAas of 31 Dec 2024 | 60.10k | 0.30% |
| BlackRock Asset Management Deutschland AGas of 05 Jun 2025 | 47.66k | 0.24% |
| Banque Cantonale Vaudoise (Investment Management)as of 31 Dec 2024 | 24.55k | 0.12% |
| DWS CH AGas of 30 Apr 2025 | 21.18k | 0.11% |
| amandea Verm�gensverwaltung AGas of 30 Sep 2024 | 14.00k | 0.07% |
| DWS Investment GmbHas of 31 Mar 2025 | 12.15k | 0.06% |
More ▼
Data from 31 Mar 2025 - 30 Apr 2025Source: FactSet Research Systems Inc.
